leisure time -WSS

leisure time

author：explore 2025-10-03 00:08:06 - browse：956

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Sutter Health’s antitrust win overturned by appeals court

WSS

Novo Nordisk touts Wegovy study, but still struggling with supply

Elevance PBM president out as customers face prescription chaos

CMS got Medicare Advantage quality rating wrong, judge rules

Timeline: How the deadly wildfires took over Maui day by day

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Senators tussle over abortion against the backdrop of a presidential campaign

hotspot

leisure time

entertainment

Alkermes shareholders re

A new initiative will help leaders fight the next pandemic

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ASCO Daily Recap: CAR

Medicare details structure of new drug price negotiation program

BMS, looking to build heart drug business, turns to AI for diagnosis

Moonlake's readout produced a cash windfall. Risks remain

Illumina slashes 2023 revenue projections yet again

Continuity nursing helped my family in our darkest PICU moments

Patients, digital health players weigh in on FTC's data privacy plan

focus

BMS, looking to build heart drug business, turns to AI for diagnosis

BD to buy Edwards patient monitoring unit for $4.2 billion

Eli Lilly’s Zepbound improved liver scarring in mid

Medicare Advantage's lean provider networks lead CMS complaints

Biden administration begins canceling student loan debt for 804,000 borrowers

Senators push IRS to launch nonprofit hospital probe

focus

focus

knowledge

hotspot